Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).

Trial Details

NCT ID
NCT05996185
Phase
PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mogamulizumab
  • DA-EPOCH Protocol
  • CHOEP protocol
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Male/female patients who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of T-cell Non-…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 unless compromised by lymphoma with anticipated benefit from chemotherapy as de…
  • Histologically confirmed T-cell Non-Hodgkin lymphoma (T-NHL), including but not limited to:
  • Peripheral T-cell lymphoma not otherwise specified (PTCL nos)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →